Literature DB >> 33596966

HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.

Tiangang Ma1, Bingdi Yan1, Yanbing Hu2, Qinghua Zhang3.   

Abstract

BACKGROUND: Previous research has highlighted the ability of Homeobox A10 (HOXA10) to the promote proliferation, migration, and epithelial-mesenchymal transformation of various cancers, including lung adenocarcinoma (LAD), which is characterized by an aggressive disease course that exhibits rapid proliferation and migration, with studies suggesting histone deacetylase 1 (HDAC1) to be a downstream mediator of HOXA10. The current study aimed to investigate the mechanism by which HOXA10-mediated HDAC1 influences the development of LAD.
METHODS: The expression patterns of HOXA10, HDAC1, DNA methyltransferase 1 (DNMT1), and Kruppel-like factor 4 (KLF4) were determined. Additionally, the effect of HOXA10, HDAC1, or DNMT1 on invasive phenotypes of LAD was analyzed using depletion experiments. The interactions among HOXA10, HDAC1, DNMT1, and KLF4 were evaluated via chromatin immunoprecipitation, dual luciferase assay or co-immunoprecipitation. Furthermore, the tumorigenic ability of the LAD cells following HOXA10 silencing and/or HDAC1 overexpression in vivo was also investigated.
RESULTS: In the LAD tissues and cells, HOXA10, HDAC1, and DNMT1 all exhibited high levels of expression, while KLF4 was poorly expressed. HOXA10 silencing inhibited the expression of HDAC1, reduced LAD cell proliferation, migration, and invasion, and promoted the apoptosis. HDAC1 promoted DNMT1 expression through deacetylation, and DNMT1 inhibited the KLF4 expression through DNA methyltransferase. The in vitro findings were further attested through the use of in vivo assays.
CONCLUSION: Taken together, the key observations of the current study highlight the role of HOXA10 and HDAC1 in promoting the proliferation and migration of LAD cells. HOXA10-induced upregulation of HDAC1 interacts with DNMT1-KLF4 axis, while the inhibition of HOXA10 or HDAC1 represents a promising anti-tumor therapy target for LAD.

Entities:  

Keywords:  DNMT1; Deacetylation; HDAC1; HOXA10; KLF4; Lung adenocarcinoma; Methylation

Year:  2021        PMID: 33596966     DOI: 10.1186/s13046-021-01867-0

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  3 in total

1.  HOXA10 promotes nasopharyngeal carcinoma cell proliferation and invasion via inducing the expression of ZIC2.

Authors:  Z-H Shen; K-M Zhao; T Du
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-03       Impact factor: 3.507

2.  Comprehensive clinical implications of homeobox A10 in 3,199 cases of non-small cell lung cancer tissue samples combining qRT-PCR, RNA sequencing and microarray data.

Authors:  Yi-Nan Guo; Bin Luo; Wen-Jie Chen; Xin Chen; Zhi-Gang Peng; Kang-Lai Wei; Gang Chen
Journal:  Am J Transl Res       Date:  2019-01-15       Impact factor: 4.060

Review 3.  The revised TNM staging system for lung cancer.

Authors:  Ramon Rami-Porta; John J Crowley; Peter Goldstraw
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 1.520

  3 in total
  3 in total

1.  miR-195-3p alleviates homocysteine-mediated atherosclerosis by targeting IL-31 through its epigenetics modifications.

Authors:  Jiantuan Xiong; Fang Ma; Ning Ding; Lingbo Xu; Shengchao Ma; Anning Yang; Yinju Hao; Huiping Zhang; Yideng Jiang
Journal:  Aging Cell       Date:  2021-09-30       Impact factor: 9.304

2.  +HOXA10-AS Promotes Malignant Phenotypes of Gastric Cancer via Upregulating HOXA10.

Authors:  Fengyu Cao; Yongbin Zheng; Chao Yang; Suoyang Huang; Xiaobo He; Shilun Tong
Journal:  Comput Math Methods Med       Date:  2022-02-16       Impact factor: 2.238

3.  The Potential Mechanism of HDAC1-Catalyzed Histone Crotonylation of Caspase-1 in Nonsmall Cell Lung Cancer.

Authors:  Chuan Jiang; Jiangrong Liao; Fang Yang; Ting Jiang; Dan Zhang; Yuanjun Xin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-02       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.